Holen Sie sich die Stockscreener-App
203.69
0.60%
-1.23
Vorhandelsmarkt:
208.65
4.96
+2.44%
Schlusskurs vom Vortag:
$204.92
Offen:
$204.75
24-Stunden-Volumen:
1.49M
Relative Volume:
1.08
Marktkapitalisierung:
$29.17B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-124.11
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
+3.44%
1M Leistung:
-0.84%
6M Leistung:
-11.68%
1J Leistung:
+34.81%
1-Tages-Spanne:
$198.97
$210.00
1-Wochen-Bereich:
$184.81
$210.00
52-Wochen-Spanne:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
203.69 | 29.35B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
449.37 | 167.89B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
173.33 | 121.11B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
553.07 | 43.67B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
340.99 | 33.51B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.79 | 32.15B | 7.07B | 1.29B | 993.00M | 4.5355 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology - BioSpace
Natera to present 35 oncology abstracts at ASCO meeting - Investing.com UK
Mid-Cap Stocks Analysis: Natera to Buy, Graco and Jacobs Solutions to Sell | StockStoryNews and Statistics - IndexBox
Natera to present 35 oncology abstracts at ASCO meeting By Investing.com - Investing.com Canada
35 Natera studies test ctDNA to flag cancer return at ASCO - Stock Titan
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone - Yahoo Finance
Natera announces expansion into Austin, creating largest sequencing factory - TipRanks
Natera Expands Operations in Austin - Moomoo
Natera expands Austin facility, plans to add 400 jobs - Investing.com
Natera expands Austin facility, plans to add 400 jobs By Investing.com - Investing.com Canada
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World - Yahoo Finance Singapore
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling? - Kavout
Natera (NTRA) Expands Clinical Trial Enrollment to Over 2,000 Pa - GuruFocus
Natera Expands Enrollment in Fetal Genetic Testing Study - Moomoo
Quinn Emanuel Gets $3 Million Sanction in Drug Advertising Case - Bloomberg Law News
Natera’s EXPAND trial enrolls over 2,000 patients By Investing.com - Investing.com Australia
Natera’s EXPAND trial enrolls over 2,000 patients - Investing.com
Study of prenatal gene risk test now passes 2,000 patients - Stock Titan
FDA Nod For Signatera MRD Blood Test Might Change The Case For Investing In Natera (NTRA) - simplywall.st
Is It Time To Reassess Natera (NTRA) After The Recent Share Price Pullback - Yahoo Finance
Natera jumps after Signatera CDx wins FDA companion diagnostic approval in bladder cancer - Quiver Quantitative
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer - The Globe and Mail
Natera wins FDA approval for companion diagnostic - MedTech Dive
What's Behind Natera CEO Steven Chapman's Recent Stock Sales - Kavout
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call - Yahoo Finance
A Look At Natera (NTRA) Valuation After Recent Share Price Weakness - simplywall.st
Natera, Inc. (NTRA) Investor Outlook: Exploring A 39.99% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Natera, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman - GuruFocus
Natera Inc stock (US6323071042): insider selling and a sharp pullback unsettle investors - AD HOC NEWS
Natera Scores Rare FDA Approval but Shares Drop - TechStock²
Natera co-founder Sheena Jonathan sells $959,450 in company stock - Investing.com India
Natera co-founder Sheena Jonathan sells $959,450 in company stock By Investing.com - Investing.com UK
Natera (NTRA) co-founder Jonathan Sheena sells 4,650 shares under 10b5-1 plans - Stock Titan
New blood test helps tailor bladder cancer treatment, wins FDA backing - Stock Titan
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod - Fierce Pharma
Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer - Moomoo
Natera Gets FDA Approval for Bladder-Cancer Test - marketscreener.com
Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) - Business Wire
NTRA Technical Analysis | Trend, Signals & Chart Patterns | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera’s Stronghold in Cancer Recurrence Tests Prompts Wood’s Ark to Expand Stake - The Daily Upside
(NTRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Cancer Test That Wall Street Is Betting On - WSJ
Natera, Inc.Common Stock (NQ: NTRA - FinancialContent
Natera NTRA Q1 2026 Earnings Call Transcript - AOL.com
Natera (NTRA) Sees Recent Investment Surge from ARK Investment - GuruFocus
Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock - Investing.com India
Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock By Investing.com - Investing.com South Africa
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report - simplywall.st
Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Moomoo
Why Natera (NTRA) Shares Are Plunging Today - Yahoo Finance
Natera price target raised to $249 from $240 at Piper Sandler - TipRanks
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.03%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):